WHO Conditionally Recommends GLP-1 Therapies for Obesity Treatment
Meta Description: The World Health Association issued it’s first guideline on GLP-1 medications for obesity, conditionally recommending their use as part of long-term care for the disease affecting over 1 billion people globally.
The World Health Organization (WHO) released its first-ever guideline on Monday,October 1st,conditionally recommending GLP-1 therapies as a component of long-term treatment for obesity,a chronic condition impacting more than one billion individuals worldwide. The move signals a notable shift in how the global health body views and addresses the growing obesity epidemic.
Acknowledging Obesity as a chronic Disease
The guidance arrives amid surging global demand for GLP-1 agonists, a class of drugs increasingly sought after for weight management, and as governments grapple with integrating these frequently enough-expensive therapies into public health systems. The WHO’s Director-General, Tedros Adhanom Ghebreyesus, stated that the measure “recognizes that obesity is a chronic disease that can be treated with comprehensive, lifelong care,” but cautioned that medication alone is insufficient to resolve the global health crisis.
The recommendations are twofold: the first advises the use of GLP-1 medications for adults – excluding pregnant women – in the long-term management of obesity. The second emphasizes combining these medications with a healthy diet and regular physical activity.
Conditional Recommendations and Ongoing Research
According to a researcher from the University of Cambridge, the recommendations were “appropriately classified as conditional,” reflecting existing uncertainties surrounding the long-term effects of higher doses, affordability, and the capacity of healthcare systems to support widespread implementation. This cautious approach underscores the need for continued research and monitoring as these therapies become more prevalent.
Equitable Access Remains a Critical Challenge
A central concern highlighted by WHO officials is ensuring equitable access to GLP-1 therapies. Despite anticipated increases in production, projections indicate that these medications will reach less than 10% of those who could benefit by 2030. “Our biggest concern is equitable access; without coordinated action, these medicines could contribute to widening inequality between rich and poor, both between and within countries,” Tedros warned.
The agency is advocating for expanded production, improved affordability, and the implementation of procurement mechanisms – mirroring prosperous strategies used in large-scale health programs like HIV treatment – to ensure broader access.
Building on Previous Actions & Expanding the essential Medicines List
This latest guidance builds upon the WHO’s decision in September to include semaglutide and tirzepatide – the active ingredients in Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro, respectively – on its list of essential medicines for treating type 2 diabetes in high-risk groups. However, these medications were not initially added to the list for obesity treatment.
The current guideline applies to adults with a Body Mass Index (BMI) of 30 or greater and specifically recommends three medications: semaglutide, tirzepatide, and the older liraglutide.
Prioritizing Access and Addressing Economic Impact
The WHO plans to collaborate with governments and stakeholders in 2026 to prioritize access for those most in need. This effort is especially crucial given the projected economic impact of obesity, which is expected to reach US$3 trillion annually by 2030.Addressing this escalating cost will require a multifaceted approach, including preventative measures and accessible treatment options.
